Medical Cannabis Significantly Improves Quality of Life, Finds Europe’s Largest Patient Study
Project Twenty21, Europe’s largest ever medical cannabis patient study, has released its first preliminary results – the first real-world data to be published on medical cannabis patients in the United Kingdom.
THC and CBD Can Reduce Neural Activity in Juvenile Zebrafish, Study Finds
As zebrafish are accepted models for humans in scientific research (much like mice), the authors of the study say that these observed effects of prenatal cannabis exposure could be mirrored in humans.
Harsh European Cannabis Laws Don’t Deter Frequent Consumers, Study Finds
The researchers found that while restrictive intervention does appear to decrease the share of adolescents initiating cannabis use, there was no evidence of policy changes impacting the share of frequent cannabis users.
MDMA-assisted Therapy Can Successfully Treat PTSD, Study Finds
The use of MDMA-assisted therapy for post-traumatic stress disorder (PTSD) has now proven itself in its first phase 3 clinical trial.
Parental Consumption Shapes How Teens Use Cannabis
Research shows understanding teen use helps develop effective prevention programs.
Older Adults with Functional Impairments Linked to Prescription Drug Misuse
Study finds adults age 50 and older with functional impairments use medical cannabis more and are more likely to suffer from prescription opioid and tranquilizer/sedative use and misuse.
FDA Grants Authorization Allowing Research Institute to Study Psychedelic Use by Therapists
This comes after the FDA also recently allowed institutes to conduct clinical trials on MDMA and its therapeutic potential in treating PTSD.
Synthetic Psychedelic Reduces Stress in Mice, Study Finds
Crucially, the scientists say, the benefits of the drug came without the cost of hallucinations, a side effect which may aggravate stress.
Denmark Extends its Medical Cannabis Trial
The trial was due to expire this December, but the Danish government has announced that parts of the scheme will be extended for another four years.
